Venous thromboembolism risk in sarcoma patients receiving combined immune checkpoint inhibitors and VEGF pathway inhibitors: a real-world cohort study
Rahul Kumar, Rohan A Phadke, Andrew Bouras, Harlene Kaur, Samer G Salman, Sai Sarnala, Swapna Vaja, Dylan Riley, Samuel W Rice, Marta Batus, Alan Blank · 2026
Read Venous thromboembolism risk in sarcoma patients receiving combined immune checkpoint inhibitors and VEGF pathway inhibitors: a real-world cohort study by Rahul Kumar, Rohan A Phadke, Andrew Bouras, Harlene Kaur, Samer G Salman, Sai Sarnala, Swapna Vaja, Dylan Riley, Samuel W Rice, Marta Batus, Alan Blank (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13357106.txt.
Description
Rahul Kumar and co-authors studied in 2026 whether adding a blood-vessel-blocking drug to immune therapy raises clot risk in sarcoma patients. Both drug classes can promote clots on their own, but the combined risk in these bone and soft tissue cancers was unmeasured. Using a large United States health network, they matched 834 patients on combined therapy with 834 on immune therapy alone.
At one year, dangerous clots struck 14.0 percent of the combined group and 12.4 percent of the single-drug group, a gap too small to rule out chance. Muscle and joint side effects were similar. The authors stress the high overall clot burden and urge risk checks.
Catalog record
| CREATOR | Rahul Kumar, Rohan A Phadke, Andrew Bouras, Harlene Kaur, Samer G Salman, Sai Sarnala, Swapna Vaja, Dylan Riley, Samuel W Rice, Marta Batus, Alan Blank |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30551 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |